Sugi Predict

Sugi Predict / Compounds / SCHEMBL3485953

SCHEMBL3485953

SCHEMBL3485953

O=C(Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 1.00
▸ RIN1 Q13671 1/20 1.00
▸ POLB P06746 1/20 0.64
▸ P2RY6 Q15077 2/20 0.49
▸ P2RY14 Q15391 2/20 0.49
▸ NT5E P21589 1/20 0.49
▸ CYP1A2 P05177 1/20 0.47
▸ MAPT P10636 3/20 0.43
▸ HTT P42858 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ LMNA P02545 4/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ ALB P02768 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ ROCK2 O75116 1/20 0.37
▸ CCNA2 P20248 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13170024 1.00 ABL1 (1.00) ABL1RIN1POLBP2RY6P2RY14
SCHEMBL13233886 0.87 ABL1 (0.75) ABL1RIN1POLBP2RY6P2RY14
SCHEMBL14429041 0.86 ABL1 (0.75) ABL1RIN1POLBP2RY6P2RY14
SCHEMBL13557957 0.86 ABL1 (0.75) ABL1RIN1POLBP2RY6P2RY14
SCHEMBL25706087 0.85 ABL1 (0.74) ABL1RIN1POLBP2RY6P2RY14
SCHEMBL10513648 0.85 ABL1 (0.74) ABL1RIN1POLBCYP1A2ROCK2
SCHEMBL13415574 0.85 ABL1 (0.74) ABL1RIN1POLBP2RY6P2RY14
SCHEMBL10330290 0.85 ABL1 (0.73) ABL1RIN1POLBP2RY6P2RY14
SCHEMBL10509318 0.84 ABL1 (0.73) ABL1RIN1POLBCYP1A2MAPT
SCHEMBL14568600 0.83 ABL1 (0.71) ABL1RIN1POLBP2RY6P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3682903-A1 MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION GERON CORPORATION (US) 2020-07-22 — — EP disclosed
EP-3342425-B1 MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION GERON CORP (US) 2019-12-18 — — EP disclosed
US-10196641-B2 Modified oligonucleotides for telomerase inhibition GERON CORPORATION (US) 2019-02-05 — — US disclosed
EP-1667522-B1 MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION GERON CORP (US) 2018-01-17 — — EP disclosed
US-9657296-B2 Modified oligonucleotides for telomerase inhibition GERON CORPORATION (US) 2017-05-23 — — US disclosed
US-20170130225-A1 MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION GERON CORPORATION 2017-05-11 — — US disclosed
US-9572891-B2 Oligonucleotide conjugates GERON CORPORATION (US) 2017-02-21 — — US disclosed
US-9404112-B2 Modified oligonucleotides for telomerase inhibition GERON CORPORATION (US) 2016-08-02 — — US disclosed
US-9388415-B2 Modified oligonucleotides for telomerase inhibition BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) 2016-07-12 — — US disclosed
US-9388416-B2 Modified oligonucleotides for telomerase inhibition BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) 2016-07-12 — — US disclosed
US-6835826-B2 Acid resistance, stability; telomerase inhibitor GERON CORPORATION 2004-12-28 — — US disclosed
EP-1379689-A4 OLIGONUCLEOTIDE CONJUGATES GERON CORP (US) 2004-04-14 — — EP disclosed
WO-2004029277-A2 OLIGONUCLEOTIDE CONJUGATES GERON CORPORATION (US) 2004-04-08 — — WO disclosed
EP-1379689-A2 OLIGONUCLEOTIDE CONJUGATES Geron Corporation (US) 2004-01-14 — — EP disclosed
US-20030212032-A1 Acid resistance, stability; telomerase inhibitor GERON CORPORATION 2003-11-13 — — US disclosed
US-6608036-B1 Inhibit telomerase enzyme activity; inhibit proliferation of cell that expresses telomerase GERON CORPORATION 2003-08-19 — — US disclosed
US-20030138814-A1 Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) GERON CORPORATION 2003-07-24 — — US disclosed
WO-2002077184-A2 OLIGONUCLEOTIDE CONJUGATES GERON CORPORATION (US) 2002-10-03 — — WO disclosed
EP-1210357-A1 OLIGONUCLEOTIDE N3'$m(7)P5' THIOPHOSPHORAMIDATES: THEIR SYNTHESIS AND USE Geron Corporation (US) 2002-06-05 — — EP disclosed
WO-2001018015-A1 OLIGONUCLEOTIDE N3'→P5' THIOPHOSPHORAMIDATES: THEIR SYNTHESIS AND USE GERON CORPORATION (US) 2001-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030138814-A1 Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) TERT, RNGTT, DUT ABL1 370/4885RIN1 3535/4885POLB 151/4885
US-20030212032-A1 Acid resistance, stability; telomerase inhibitor NT5C3B, MTAP, TERT ABL1 1671/4885RIN1 1719/4885POLB 304/4885
US-10196641-B2 Modified oligonucleotides for telomerase inhibition TERT, TRDMT1, TERF2 ABL1 2210/4885RIN1 3903/4885POLB 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.